Iovance Biotherapeutics
Jeffrey Chou, MD PhD, is a highly accomplished Senior Vice President in the field of clinical science. With an extensive background in leading roles at various pharmaceutical and research organizations, Jeffrey has made significant contributions to the study of the immune system's interaction with colorectal cancer. Through their roles at companies like Pfizer, Amgen, and Fate Therapeutics Inc, Jeffrey has demonstrated expertise in clinical development and immuno-oncology. Their educational background includes a MD, PhD in Medicine/Pathology from the University of Pittsburgh, further showcasing their dedication to advancing medical knowledge and research.
Iovance Biotherapeutics
6 followers
Iovance Biotherapeutics (NASDAQ: IOVA) aims to improve patient care for people living with cancer. Iovance is investigating T cell-based therapies, known as tumor infiltrating lymphocytes (TIL), which use a patient’s own immune cells to attack cancer.